Q-omics provides the consensus-scored VAMP7 profile across patient tissues and cancer cell-line models. VAMP7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VAMP7 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, VAMP7 RNA expression shows 19,077 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where VAMP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VAMP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VAMP7 survival associations across molecular data types. VAMP7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VAMP7 RNA expression–survival associations across cancer types. High VAMP7 expression shows unfavorable associations in HNSC, UVM and MESO, but favorable associations in KIRC, SCLC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VAMP7 RNA expression.
This table summarizes VAMP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VAMP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VAMP7 shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, LIHC, STAD and BLCA. The HNSC box plot shows higher VAMP7 RNA expression in tumor versus normal tissue (log2 FC = +0.769, t-test p < 0.001).
This table shows molecular features associated with VAMP7 in patient tissues and cancer cell lines. In patient samples, VAMP7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VAMP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
